BIONi010-C-5

BIONi010-C CD33 E2del #N14 P26

General

Cell Line

hPSCreg Name
BIONi010-C-5
Alternative name(s)
BIONi010-C CD33 E2del #N14 P26
Cell line type Human induced pluripotent stem cell (hiPSC)
Last update 13th May 2022
Notes No larger chromosomal aberrations to be reported. Chr22: 1,4Mbp duplication in q11.23
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Bioneer (BION)
Contact:
Bioneer (BSC)
Distributors
Derivation country Denmark

External Databases

BioSamples SAMEA4452061
Cellosaurus CVCL_II84
ECACC 66540367
EBiSC BIONi010-C-5
CLO CLO_0102719
Wikidata Q54796776

General Information

Publications
Projects
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: allowed
Commercial use: allowed
Subclone of

Donor Information

General Donor Information

Sex male
Ethnicity Black or African-American

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA3105780

Ethics

Also have a look at the ethics information for the parental line BIONi010-C .
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

The source cell information can be found in the parental cell line BIONi010-C.

Reprogramming method

Vector type Non-integrating
Vector Episomal
Genes
Is reprogramming vector detectable?
No

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 18 %
CO2 Concentration 5 %
Medium Essential 8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation

Analysis of Undifferentiated Cells
Morphology pictures
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Marker Expressed
CXCR4
Yes
GATA6
Yes
FOXA2
Yes
SOX17
Yes
GSC
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
Vimentin
Yes
DCN
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
PAX6
Yes
NEUROD1
Yes
HES5
Yes

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Certificate of Analysis

Is there a certificate of analysis available?
Yes
Passage: 26

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46 XY
Passage number: 27

Other Genotyping (Cell Line)

Is there genome-wide genotyping or functional data available?
Yes
Whole genome sequencing
https://ega-archive.org/studies/EGAS00001002755
This cell line has undergone WGS using the Illumina HiSeq X platform at 30x coverage. Fastq files are stored at the European Genome Archive, users can apply for access to this data by submitting an application form to the EBiSC Data Access Committee https://ega-archive.org/dacs/EGAC00001000768

Genetic Modification

Disease/phenotype related modifications
Alzheimer disease
Genetic modifications
CD33 (target)
Isogenic modification
19q13.41
Homozygous
Exon2 of the CD33 gene has been cut out by CRISPR technology
Exon2 of the CD33 gene has been cut out by CRISPR technology